Iverson Genetics
With 1,000 Enrolled, Iverson Hoping to Report First Warfarin PGx Study Outcomes Data by End of 2015
Premium
This article has been updated from an earlier version with additional information about the design and size of the WARFARIN trial. Additionally, Iverson has further clarified the difference between its study and the COAG trial.
Iverson, Johns Hopkins Ink Deal to Commercialize MDx for Heart Disease, Infertility
NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics said today it has received global exclusive rights from Johns Hopkins University School of Medicine to commercialize a molecular diagnostic test.
Columbia University of New York has received US Patent No. 8,133,492, "Pneumococcus polysaccharide-related vaccines." Nitrocellulose-based or hydrogel-based microarrays and methods of making them are claimed.
Iverson, Vanderbilt Partner on MDx for Breast Cancer Risk in Menopausal Women
NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics announced a collaboration with Vanderbilt University aimed at molecular diagnostics to assess breast cancer risk in menopausal women.
Franciscan Health System Joins WARFARIN Study; Five More Sites to Begin Enrollment in Coming Weeks
Premium
Iverson Genetic Diagnostics said this week that the Franciscan Health System in Tacoma, Wash., has begun enrolling patients for the WARFARIN (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) study that the company is leading in an effor
Aug 17, 2011
Sep 30, 2010